Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae

Sessile bacteria growing on surfaces are more resistant to standard antibiotics than their planktonic counterpart. Due to their antimicrobial properties, bacteriophages have re-emerged as a promising approach to treat bacterial biofilm-associated infections. Here, we evaluated the ability of two com...

Full description

Bibliographic Details
Main Authors: Tamta Tkhilaishvili, Lei Wang, Arianna Tavanti, Andrej Trampuz, Mariagrazia Di Luca
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Microbiology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fmicb.2020.00110/full
id doaj-38a9e40b0f09415d983af86b061eb78e
record_format Article
spelling doaj-38a9e40b0f09415d983af86b061eb78e2020-11-25T03:05:34ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2020-02-011110.3389/fmicb.2020.00110491520Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella LarvaeTamta Tkhilaishvili0Tamta Tkhilaishvili1Lei Wang2Arianna Tavanti3Andrej Trampuz4Andrej Trampuz5Mariagrazia Di Luca6Mariagrazia Di Luca7Mariagrazia Di Luca8Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Berlin Institute of Health, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Berlin Institute of Health, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, GermanyDepartment of Biology, University of Pisa, Pisa, ItalyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Berlin Institute of Health, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Berlin Institute of Health, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyDepartment of Biology, University of Pisa, Pisa, ItalySessile bacteria growing on surfaces are more resistant to standard antibiotics than their planktonic counterpart. Due to their antimicrobial properties, bacteriophages have re-emerged as a promising approach to treat bacterial biofilm-associated infections. Here, we evaluated the ability of two commercially available phage formulations, Staphylococcal bacteriophage (containing the monophage Sb-1) and PYO bacteriophage (a polyphage), in preventing and eradicating an in vitro biofilm of methicillin-resistant Staphylococcus aureus (MRSA) by isothermal microcalorimetry and high-resolution confocal laser scanning microscopy (CLSM). Moreover, to assess the potential in vivo efficacy of both phage preparations, a Galleria mellonella model of MRSA systemic infection was used. Microcalorimetry measurement showed that 107 PFU/ml (the highest tested titer) of both phage formulations were able to inhibit planktonic growth in a concentration-dependent manner. However, MRSA biofilm was eradicated only by co-incubation of 5–7 days with the highest phage titers, respectively. In the experiments of biofilm prevention, isothermal microcalorimetry revealed that the heat production was completely abolished in the presence of sub-inhibitory titers (104 PFU/ml) of phages. These data were also confirmed by confocal laser scanning microscopy. Both phage formulations increased the survival of G. mellonella larvae preventing or treating MRSA infection compared to untreated control. In conclusion, tested phage formulations are promising for preventing device colonization and killing biofilm bacteria attached on a surface. Novel strategies for direct coating and release of phages from material should be investigated.https://www.frontiersin.org/article/10.3389/fmicb.2020.00110/fullmethicillin-resistant Staphylococcus aureusbiofilm-associated infectionantimicrobial activitybacteriophagesGalleria mellonellaphage therapy
collection DOAJ
language English
format Article
sources DOAJ
author Tamta Tkhilaishvili
Tamta Tkhilaishvili
Lei Wang
Arianna Tavanti
Andrej Trampuz
Andrej Trampuz
Mariagrazia Di Luca
Mariagrazia Di Luca
Mariagrazia Di Luca
spellingShingle Tamta Tkhilaishvili
Tamta Tkhilaishvili
Lei Wang
Arianna Tavanti
Andrej Trampuz
Andrej Trampuz
Mariagrazia Di Luca
Mariagrazia Di Luca
Mariagrazia Di Luca
Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae
Frontiers in Microbiology
methicillin-resistant Staphylococcus aureus
biofilm-associated infection
antimicrobial activity
bacteriophages
Galleria mellonella
phage therapy
author_facet Tamta Tkhilaishvili
Tamta Tkhilaishvili
Lei Wang
Arianna Tavanti
Andrej Trampuz
Andrej Trampuz
Mariagrazia Di Luca
Mariagrazia Di Luca
Mariagrazia Di Luca
author_sort Tamta Tkhilaishvili
title Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae
title_short Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae
title_full Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae
title_fullStr Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae
title_full_unstemmed Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae
title_sort antibacterial efficacy of two commercially available bacteriophage formulations, staphylococcal bacteriophage and pyo bacteriophage, against methicillin-resistant staphylococcus aureus: prevention and eradication of biofilm formation and control of a systemic infection of galleria mellonella larvae
publisher Frontiers Media S.A.
series Frontiers in Microbiology
issn 1664-302X
publishDate 2020-02-01
description Sessile bacteria growing on surfaces are more resistant to standard antibiotics than their planktonic counterpart. Due to their antimicrobial properties, bacteriophages have re-emerged as a promising approach to treat bacterial biofilm-associated infections. Here, we evaluated the ability of two commercially available phage formulations, Staphylococcal bacteriophage (containing the monophage Sb-1) and PYO bacteriophage (a polyphage), in preventing and eradicating an in vitro biofilm of methicillin-resistant Staphylococcus aureus (MRSA) by isothermal microcalorimetry and high-resolution confocal laser scanning microscopy (CLSM). Moreover, to assess the potential in vivo efficacy of both phage preparations, a Galleria mellonella model of MRSA systemic infection was used. Microcalorimetry measurement showed that 107 PFU/ml (the highest tested titer) of both phage formulations were able to inhibit planktonic growth in a concentration-dependent manner. However, MRSA biofilm was eradicated only by co-incubation of 5–7 days with the highest phage titers, respectively. In the experiments of biofilm prevention, isothermal microcalorimetry revealed that the heat production was completely abolished in the presence of sub-inhibitory titers (104 PFU/ml) of phages. These data were also confirmed by confocal laser scanning microscopy. Both phage formulations increased the survival of G. mellonella larvae preventing or treating MRSA infection compared to untreated control. In conclusion, tested phage formulations are promising for preventing device colonization and killing biofilm bacteria attached on a surface. Novel strategies for direct coating and release of phages from material should be investigated.
topic methicillin-resistant Staphylococcus aureus
biofilm-associated infection
antimicrobial activity
bacteriophages
Galleria mellonella
phage therapy
url https://www.frontiersin.org/article/10.3389/fmicb.2020.00110/full
work_keys_str_mv AT tamtatkhilaishvili antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel
AT tamtatkhilaishvili antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel
AT leiwang antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel
AT ariannatavanti antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel
AT andrejtrampuz antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel
AT andrejtrampuz antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel
AT mariagraziadiluca antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel
AT mariagraziadiluca antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel
AT mariagraziadiluca antibacterialefficacyoftwocommerciallyavailablebacteriophageformulationsstaphylococcalbacteriophageandpyobacteriophageagainstmethicillinresistantstaphylococcusaureuspreventionanderadicationofbiofilmformationandcontrolofasystemicinfectionofgalleriamellonel
_version_ 1724677768306753536